345 completed. 345 Phase 3, 63 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 345 | Completed 345 |
| Phase 2 | 63 | Completed 63 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Insulin to Prevent Intensive Care Unit Delirium Intranasal insulin-40U, Intranasal sodium chloride 0.9% - Delirium - Postoperative | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 30 | 2026-04-30 | 2026-08-03 |
| Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients Dexmedetomidine nasal spray - Postoperative Delirium, Preoperative Sleep Disorder | Phase 3 | Completed | Xijing Hospital | 686 | 2025-03-03 | 2026-09-11 |
| Emergence Agitation of Sevoflurane in Pediatric we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure, we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure - Emergence Delirium | Phase 2 / Phase 3 | Completed | Ain Shams University | 126 | 2024-05-01 | 2025-02-17 |
| MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva Cannabis Sativa Oil, Placebo - Dementia with Behavioral Disturbance | Phase 2 / Phase 3 | Completed | Fondation pour l'accueil et l'hébérement des personnes âgées | 27 | 2023-09-29 | 2024-12-17 |
| Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care - Mild Cognitive Impairment, Dementia, Mild | Phase 3 | Completed | Alzheimer's Prevention and Reversal Project, Inc. | 73 | 2023-07-31 | 2026-02-18 |
| A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Semaglutide, Placebo - Alzheimers Disease | Phase 3 | Completed | Novo Nordisk A/S | 23 | 2023-06-20 | 2026-08-18 |
| Metformin Treatment on Cognitive Impairment of Schizophrenia Metformin treatment, Placebo treatment, Baseline assessments - Schizophrenia | Phase 3 | Completed | Central South University | 120 | 2023-05-08 | 2026-07-31 |
| A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD Buntanetap/Posiphen, Placebo - Alzheimer Disease | Phase 2 / Phase 3 | Completed | Annovis Bio Inc. | 351 | 2023-04-01 | 2025-04-29 |
| Nicergoline Use in Dysphagia Patients Nicergoline - Dysphagia | Phase 3 | Completed | Phramongkutklao College of Medicine and Hospital | 92 | 2023-01-01 | 2026-03-04 |
| Dexmedetomidine in Reducing Incidence of Emergence Agitation After Nasal Surgery Dexmedetomidine - Postoperative Delirium | Phase 3 | Completed | Security Forces Hospital | 42 | 2022-12-22 | 2023-04-04 |
| THRIVE Feasibility Trial Anesthetic technique Propofol TIVA, Anesthetic technique inhaled agent - Surgery--Complications, Anesthesia Complication | Phase 3 | Completed | Washington University School of Medicine | 300 | 2022-09-29 | 2023-11-24 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 408 | 2022-09-06 | 2026-08-13 |
| A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) Remternetug (IV), Remternetug (SC), Placebo - Alzheimer's Disease | Phase 3 | Completed | Eli Lilly and Company | 1667 | 2022-08-01 | 2026-05-22 |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Completed | BioXcel Therapeutics Inc | 151 | 2022-04-27 | 2026-08-11 |
| TEsting METformin Against Cognitive Decline in HD Metformin, Placebo - Huntington Disease | Phase 3 | Completed | Instituto de Investigacion Sanitaria La Fe | 60 | 2022-04-11 | 2025-09-25 |
| [18F]APN-1607 PET in Subjects With AD Compared to HC [18F]APN-1607 - Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Completed | APRINOIA Therapeutics | 230 | 2022-01-21 | 2025-09-08 |
| A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Donanemab, Aducanumab - Mild Cognitive Impairment (MCI), Alzheimer Disease | Phase 3 | Completed | Eli Lilly and Company | 148 | 2021-11-16 | 2024-11-29 |
| Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Completed | Cassava Sciences, Inc. | 804 | 2021-11-03 | 2025-05-25 |
| Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study Nefopam, Standard of care in the ICU for assessment and management of pain, sedation, and delirium. - Analgesia, Critical Illness | Phase 3 | Completed | Cairo University | 60 | 2021-10-01 | 2025-12-19 |
| Effect of Raisins on Cognitive Function in Healthy Older Adults Raisins - Cognitive Dysfunction | Phase 3 | Completed | University of Salamanca | 80 | 2021-09-20 | 2023-12-19 |
Showing 20 of 345. Sign in to see all of them.
Alzheimer Disease (193) · Dementia (80) · Cognitive Dysfunction (66) · Delirium (32) · Psychomotor Agitation (24) · Memory Disorders (23) · Cognition Disorders (19) · Dementia, Vascular (17) · Emergence Delirium (16) · Huntington Disease (15) · Mental Disorders (11) · Brain Diseases (10) · Stroke (10) · Depression (9) · Consciousness Disorders (8)
Mental Disorders (334) · Nervous System Diseases (309) · Central Nervous System Diseases (255) · Brain Diseases (247) · Neurodegenerative Diseases (207) · Tauopathies (191) · Dementia (164) · Pathological Conditions, Signs and Symptoms (129) · Signs and Symptoms (117) · Neurologic Manifestations (114) · Neurobehavioral Manifestations (103) · Cognition Disorders (81) · Confusion (46) · Behavior (44)
Galantamine (21) · Donepezil (19) · Dexmedetomidine (14) · Memantine (11) · Rivastigmine (9) · florbetapir (8) · Aripiprazole (6) · Saline Solution (6) · flutemetamol (6) · Melatonin (5) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (4) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (4) · Docosahexaenoic Acids (4) · Haloperidol (4) · Risperidone (4)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (15) · Otsuka Pharmaceutical Development & Commercialization, Inc. (12) · Eli Lilly and Company (11) · National Institute on Aging (NIA) (10) · Assistance Publique - Hôpitaux de Paris (9) · Avid Radiopharmaceuticals (9) · Pfizer (7) · GE Healthcare (6) · Novartis Pharmaceuticals (6) · VA Office of Research and Development (6) · Eisai Inc. (5) · H. Lundbeck A/S (5) · Novartis (5) · Axsome Therapeutics, Inc. (4) · TauRx Therapeutics Ltd (4)
United States (197) · Canada (72) · France (55) · Germany (50) · United Kingdom (46) · Spain (41) · Australia (39) · Italy (35) · Poland (26) · Netherlands (22) · Russia (21) · South Korea (20) · Sweden (20) · Japan (19) · Brazil (18)
Leon Thal, MD. (3) · Mary Sano, PhD (3) · Jacobo Mintzer, MD (2) · Jane Yardley, Ph.D (2)
PMID 39498781, PMID 39800465, PMID 26120369, PMID 26402769, PMID 40681915, PMID 41533472, PMID 41961243, PMID 29318278, PMID 30474567, PMID 31193334, PMID 33189083, PMID 39108660, PMID 41591746, PMID 20921879, PMID 22749065, PMID 24450890, PMID 24450891, PMID 25125457, PMID 26208959, PMID 27494299, PMID 28265459, PMID 28269765, PMID 29615123, PMID 29854934, PMID 29854935, PMID 30412493, PMID 30558645, PMID 31353964, PMID 31708380, PMID 31831056, PMID 32107748, PMID 32524297, PMID 33070419, PMID 33587110, PMID 34923848, PMID 36627206, PMID 36715498, PMID 36946603, PMID 37434378, PMID 37943223, PMID 38557959, PMID 38932583, PMID 39177596, PMID 39825184, PMID 40488446, PMID 40603145, PMID 40847656, PMID 41439450, PMID 41689409, PMID 42052145
U01AG010483 (5), 2016 (4), 2017 (3), 1RC2AG036535 (2), 2009 (2), 2015 (2), 2018 (2), 2023 (2), 2004 (1), 2008 (1), 2025 (1), 3UG1CA189824-04S1 (1), F32MH075583 (1), I01RX001507 (1), P50AT000066 (1)